Mar De Miguel

1 week ago | bioworld.com | Mar De Miguel

How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...

2 weeks ago | bioworld.com | Mar De Miguel

Home » Gut microbiome leads to metabolic and immune changes after transplantGastrointestinalGut microbiome leads to metabolic and immune changes after transplantIs fecal microbiota transplant effective? Is it really safe? And is it really all the same? Scientists at the University of Chicago have investigated the regional differences in gut environments to question these interventions. BioWorld Science Science Gastrointestinal

2 weeks ago | bioworld.com | Mar De Miguel

GastrointestinalGut microbiome leads to metabolic and immune changes after transplantIs fecal microbiota transplant effective? Is it really safe? And is it really all the same? Scientists at the University of Chicago have investigated the regional differences in gut environments to question these interventions to analyze the microbiome differences and their effects after transplantation form different intestine areas.

2 weeks ago | bioworld.com | Mar De Miguel

Home » Gut microbiome leads to metabolic and immune changes after transplant BioWorld briefs for June 9, 2025. BioWorld MedTech briefs for June 9, 2025. In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant... Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company... Omada Health Inc.

3 weeks ago | bioworld.com | Mar De Miguel

Home » Epigenetics tells the story of aging blood cells BioWorld briefs for June 4, 2025. BioWorld MedTech briefs for June 4, 2025. The row between pharma companies and the U.K. government over rebates has intensified, with the Association of the British Pharmaceutical Industry calling up its... BioWorld Asia briefs for June 3, 2025 It’s a good week to be working on drugs targeting STAT6. Kymera Therapeutics Inc.’s, KT-621, the first oral STAT6 degrader candidate to enter the clinic,...